Literature DB >> 8760171

Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors.

R Natarajan1, L Lanting, N Gonzales, J Nadler.   

Abstract

Recently a series of non-cyclooxygenase-derived prostanoids were identified in vivo in humans and in animal models of free radical injury as products of free radical-catalyzed peroxidation of arachidonic acid. One of these, an F2-isoprostane, 8-epiprostaglandin F2 alpha (8-epi-PGF 2 alpha), is a potent renal vasoconstrictor and can increase vascular smooth muscle cell (VSMC) DNA synthesis. In the present study we have evaluated whether F2-isoprostanes play a role in diabetic vascular dysfunction by studying the formation of 8-epi-PGF2 alpha in porcine VSMC (PVSMC) cultured under hyperglycemic conditions. 8-Epi-PGF2 alpha levels were quantitated by a specific enzyme immunoassay. We also examined whether certain VSMC growth factors, such as angiotensin II, platelet-derived growth factor, and transforming growth factor-beta, could also regulate the formation of 8-epi-PGF2 alpha. We observed that PVSMC cultured under high glucose (HG) conditions produced significantly higher amounts of 8-epi-PGF2 alpha compared with normal glucose (NG) conditions (3.7 +/- 0.13 ng/10(6) cells in HG vs. 2.9 +/- 0.2 ng/10(6) cells in NG, P < 0.05). Furthermore, all three growth factors tested evoked significant dose-dependent formation of 8-epi-PGF2 alpha (ranging from 125 to 220% of control). These results suggest that 8-epi-PGF2 alpha formation, as a result of hyperglycemia or due to growth factor action, may lead to increased VSMC growth and contribute to the complications of diabetes and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760171     DOI: 10.1152/ajpheart.1996.271.1.H159

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis.

Authors:  C E Collins; P Quaggiotto; L Wood; E V O'Loughlin; R L Henry; M L Garg
Journal:  Lipids       Date:  1999-06       Impact factor: 1.880

2.  A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid.

Authors:  Evgenia Alpert; Arie Gruzman; Hanan Totary; Nurit Kaiser; Reuven Reich; Shlomo Sasson
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

3.  F(2)-isoprostanes as novel biomarkers for type 2 diabetes: a review.

Authors:  Subramanian Kaviarasan; Sekaran Muniandy; Rajes Qvist; Ikram S Ismail
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

4.  Inflammation and oxidative stress markers in diabetes and hypertension.

Authors:  Chloé Pouvreau; Antoine Dayre; Eugene G Butkowski; Beverlie de Jong; Herbert F Jelinek
Journal:  J Inflamm Res       Date:  2018-02-19

Review 5.  Postprandial hyperglycemia as an etiological factor in vascular failure.

Authors:  Koichi Node; Teruo Inoue
Journal:  Cardiovasc Diabetol       Date:  2009-04-29       Impact factor: 9.951

6.  Glycemic variability: Clinical implications.

Authors:  Surabhi Venkata Satya Krishna; Sunil K Kota; Kirtikumar D Modi
Journal:  Indian J Endocrinol Metab       Date:  2013-07

7.  Genetic risk score of common genetic variants for impaired fasting glucose and newly diagnosed type 2 diabetes influences oxidative stress.

Authors:  Minjoo Kim; Minkyung Kim; Limin Huang; Sun Ha Jee; Jong Ho Lee
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.